This is a randomized controlled trial to evaluate the efficacy of ivermectin in COVID-19 outpatients reducing the risk of progression to severe disease.~Patients with COVID-19 infection are randomized to receive a single dose of 200mcg/kg of ivermectin or a placebo.~The randomization code is generated by the trial statistician. The allocation is made after fulfilment of both inclusion and exclusion criteria.
This is a randomized controlled trial to evaluate the efficacy of ivermectin in reducing the risk of progression to severe disease and hospitalizations in COVID-19 patients.